By Angela McDaniels
Seattle, Jan. 6 - Athenix Corp. said it has raised $13 million in growth capital through a series C venture capital investment.
The series C round was led by new investor Finistere Partners and included Intersouth Partners, Polaris Venture Partners, Boston Millennia Partners, Hunt Ventures and Eastman Ventures.
Athenix said it will use the proceeds to continue moving products through field trials to registration. Key products include major crops with enhanced traits such as tolerance to common herbicides and resistances to pests such as nematodes and insects.
"Athenix is an exciting investment opportunity. The company continues to make excellent progress and is poised to become a key provider of high-value traits for transgenic plants," Jerry Caulder of Finistere Partners said in a company news release.
Athenix is a biotechnology company based in Research Triangle Park, N.C., that discovers and develops products, technologies and processes for the agricultural and chemical businesses.
| Issuer: | Athenix Corp.
|
| Issue: | Series C venture capital
|
| Amount: | $13 million
|
| Investors: | Finistere Partners, Intersouth Partners, Polaris Venture Partners, Boston Millennia Partners, Hunt Ventures and Eastman Ventures
|
| Announcement date: | Jan. 6
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
